Vivos Therapeutics Leads the Battle Against Obstructive Sleep Apnea (OSA)

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Sleeping well plays an essential role in physical health. In fact, it is part of the recovery, healing and repair process of many body functions. A lack of sleep can result in daytime drowsiness, anxiety and reduction of attention that can impact negatively on performance.

Additionally, sleep deficiency and associated breathing disorders have been linked to a higher risk of heart disease, diabetes, dementia, high blood pressure, kidney disease and stroke, among others.

Obstructive sleep apnea (OSA) is a common chronic disease in the world with approximately 1 billion people suffering from it. In fact, as many as 80% of this number remain undiagnosed. According to NCBI, left untreated, OSA may increase the risk of comorbidities such as high blood pressure/hypertension, heart failure and stroke.

Vivos Therapeutics Inc. VVOS, a medical technology company focused on developing and commercializing innovative solutions for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea, understands the importance of offering patients comfortable options beyond the continuous positive airway pressure (CPAP) machine.

Here's how Vivos Therapeutics approaches OSA.

The Vivos System

According to the Mayo Clinic, OSA occurs when the muscles in the back of the throat relax and the airway narrows or closes as the person attempts to breathe in. Not getting enough air can lower the oxygen levels in the blood, and when the brain senses the inability to breathe, it briefly rouses from sleep so it can reopen the airway.

A patient with OSA might snort, choke or gasp during an apnea event. This pattern of apneas can repeat itself 5 to 30 times or more each hour, all night, impairing the ability to reach the deep, restful phases of sleep.
The Vivos System is a multi-disciplinary therapeutic protocol featuring the Vivos mRNA Oral Appliance. The Vivos System combines the use of oral appliance specifications developed by Vivos and prescribed by specially trained independent dentists in cooperation with their medical colleagues.
This system is indicated for use to treat mild-to-moderate obstructive sleep apnea, snoring and sleep-disordered breathing in adults. It is a non-surgical, non-invasive and cost-effective alternative designed to promote the proper growth and development of the tissues surrounding the oral cavity, nasal cavity, upper and lower jaws, and other tissues that form and shape the upper airway.

As these areas develop more fully using the Vivos System, a patient's airway typically widens and expands, enabling them to breathe properly through their nose.
The average treatment is approximately 18-24 months for most cases, and it may improve facial aesthetics. Vivos Therapeutics is a registered with the FDA as a specification developer and has had FDA registrations and clearance since 2009.

The New VivoScore

The new VivoScore is a comprehensive home sleep test ("HST") that uses proprietary cardiopulmonary coupling technology developed by MyCardio LLC ("SleepImage"). VivoScore consists of a single-sensor ring recorder that works with a mobile phone application and cloud-based algorithms to evaluate sleep quality and allow a qualified doctor to clinically diagnose sleep apnea.

Corporate Highlights

The Company reported a revenue increase of 15% for 2020 of $13.1 million compared to $11.4 million in 2019.
In March 2021, the Company announced the opening of the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center featuring the Vivos System through its Medical Integration Division.
In February 2021, the company submitted a 510(k) Class II application to the U.S. Food and Drug Administration (FDA) for its mmRNA oral appliance with indications to treat mild-to-moderate OSA, sleep-disordered breathing and snoring in adults.
In January 2021, the Company established a Clinical Advisory Board to further drive the adoption and growth of its next-generation treatments for OSA
The Company announced in January 2021 its commercial launch of AireO2, a new patient management software technology that will enable healthcare professionals to more effectively diagnose, treat and monitor patients with OSA and its related conditions.
The Company announced in December 2020 the closing of its initial public offering of 4,025,000 shares of its common stock.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.